Speciality
Spotlight

       




 


Medicine


   

 




Albumin
Use in ICU

  

  • Robert
    I

    Human
    Albumin Administration in Critically Ill Patients :
    Systematic Review of Randomized Controlled Trials

    BMJ
    317: 235-240, 1998

     

    The
    risk of death increases inversely with the decrease
    in serum albumin in critically ill patients.
    Because human albumin is very expensive
    compared with other colloid solutions, its use
    should be limited to those who can benefit. A
    systematic review of randomized, controlled trials
    was conducted to quantify the effects on mortality
    of critically ill patients with hypovolemia and
    hypoprotenemia.

      

    Thirty
    randomized trials, involving 1419 patients, were
    identified. Patients were categorized by type of injury and intervention.
    Mortality from all causes was tallied.

     

    After
    administration of albumin, the relative risks of
    death from hypovolemia, burns, and hypoalbuminemia
    were 1.46, 2.40 and 1.69 respectively.
    The pooled risk of death was 1.68.
    The pooled difference in the risk of death
    after albumin administration was 6 deaths for every
    100 patients treated.

     

    It
    was observed albumin administration did not decrease
    mortality and may, indeed, increase mortality in
    critically ill patients with hypovolemia, burns, and
    hypoalbuminemia. The
    practice of administering human albumin to
    critically ill patients should be reviewed.

         

 



 

           

Speciality Spotlight

       

 
Medicine
   

 

Albumin Use in ICU
  

  • Robert I
    Human Albumin Administration in Critically Ill Patients : Systematic Review of Randomized Controlled Trials
    BMJ 317: 235-240, 1998
     
    The risk of death increases inversely with the decrease in serum albumin in critically ill patients. Because human albumin is very expensive compared with other colloid solutions, its use should be limited to those who can benefit. A systematic review of randomized, controlled trials was conducted to quantify the effects on mortality of critically ill patients with hypovolemia and hypoprotenemia.
      
    Thirty randomized trials, involving 1419 patients, were identified. Patients were categorized by type of injury and intervention. Mortality from all causes was tallied.
     
    After administration of albumin, the relative risks of death from hypovolemia, burns, and hypoalbuminemia were 1.46, 2.40 and 1.69 respectively. The pooled risk of death was 1.68. The pooled difference in the risk of death after albumin administration was 6 deaths for every 100 patients treated.
     
    It was observed albumin administration did not decrease mortality and may, indeed, increase mortality in critically ill patients with hypovolemia, burns, and hypoalbuminemia. The practice of administering human albumin to critically ill patients should be reviewed.
         

 

 

By |2022-07-20T16:42:08+00:00July 20, 2022|Uncategorized|Comments Off on Albumin Use in ICU

About the Author: